Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Would you consider prescribing a JAK inhibitor for a patient with a history of DVT who is on chronic anticoagulation, or would the thrombotic risk deter you?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
What is your typical steroid taper regimen for managing RA flares?
Have you seen synovitis (even if subtle) with aromatase inhibitor musculoskeletal syndrome?
How would you manage a patient with RA with newly diagnosed T-LGLL who was previously treated with Enbrel and is now flaring off Enbrel while on low dose methotrexate?
Would you use TNF inhibitor therapy in a patient with seropositive RA who had optic neuritis as a child without relapse as an adult?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
